Sativex regulatory update

GW Pharmaceuticals said France recommended approval of Sativex to treat spasticity due to multiple sclerosis (MS) under the European Mutual Recognition Procedure. GW expects France will issue a national marketing authorization after finalizing any country-specific requirements. GW's European marketing partner Almirall S.A. (Madrid:ALM, Barcelona, Spain) will commercialize Sativex in France. In June, the French Minister of Health signed a decree to amend French legislation to permit the prescription of a cannabis-based medicine, subject to approval by French National Agency of Medicine and Health Products Safety (ANSM). ...